Elemental Analysis Inc., a privately held trace element analysis firm, today released a white paper which examines purity testing levels with applications to nano-technology in the healthcare and nano-medicine sectors. The rise of nano-technology, combined with tight healthcare guidelines, require highly accurate purity testing levels for manufacturing production.
The white paper reveals that irradiation testing of nano-medicines and nano-delivery devices can insure detection of contaminants to levels as sensitive as one part per quadrillion for 40 trace elements, including gold. Unlike other test methods, no sample pre-treatment is required for the analysis.
"At the nano levels, many elements may have different properties than at the macro level," states Mark Stauffer, of Elemental Analysis, "this 'ultra trace detection' capability enables our customers to take their products to market with full confidence that the purity levels required for performance are there."
For companies in the pharmaceutical and medical delivery fields, nano-level testing means that the error margin for the purity of their products is narrowed. Testing can turn around in as little as three days, speeding the process up substantially from current market wait times as long as three months.
To obtain a copy of the study, entitled "Growth in Nano-Sector Healthcare Requires Unparalleled Test Accuracy," visit http://www.ElementalAnalysis.com/pressroom.asp
About Elemental Analysis
Elemental Analysis, Inc. (EAI), a privately held company, provides all segments of industry with trace element analysis to determine product compositions and potential contamination levels. The company utilizes both non-destructive and state of the art forms of analytical chemistry with limits of detection ranging from sub-percent, to as low as parts-per-quadrillion.